/

Empresas

Su

No verificado

Summit Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

43 Comunicados de prensa

Ver todos los comunicados de prensa

22/09/2026

Industria

Eventos

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Oncología

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

Fuente

Summit Therapeutics

Editor

1.00

0

15/09/2026

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

Eventos

Industria

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

Fuente

Summit Therapeutics

Editor

1.00

0

13/09/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Mercado laboral

Eventos

Industria

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

Fuente

Summit Therapeutics

Editor

1.00

0

02/09/2026

Industria

Ciencia

Biotecnología

Medicina - Varios

Sanidad

Farmacéutica

Salud

Oncología

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

Fuente

Summit Therapeutics

Editor

1.00

0

25/08/2026

Análisis de Mercados

Industria

Ciencia

Medicina - Varios

Sanidad

Biotecnología

Farmacéutica

Salud

Oncología

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

Fuente

Summit Therapeutics

Editor

1.00

0

25/08/2026

Industria

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

Fuente

Summit Therapeutics

Editor

1.00

0

12/08/2026

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Fuente

Summit Therapeutics

Editor

1.00

0

05/08/2026

Análisis de Mercados

Industria

Ciencia

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Oncología

Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer

Fuente

Summit Therapeutics

Editor

1.00

0

23/07/2026

Web y redes sociales

Telefonía

Mercado de valores

Ciencia

Higiene alimentaria

Medicina - Varios

Biotecnología

Sanidad

Farmacéutica

Salud

Oncología

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Fuente

Summit Therapeutics

Editor

1.00

0

22/07/2026

Mercado laboral

Ciencia

Higiene alimentaria

Medicina - Varios

Sanidad

Biotecnología

Farmacéutica

Salud

Oncología

Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer

Fuente

Summit Therapeutics

Editor

1.00

0

Seguidores

0

Compatibilidad

0